A proposal to reorganize FDA's medical product offices from a modality-based structure to one oriented by therapeutic area could gain more traction with the Senate's forthcoming draft of its medical innovation legislation.
A Friends of Cancer Research (FOCR) proposal to realign FDA according to disease area is drawing mixed reviews from current and former agency officials. Some say the agency's structure needs...